within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DD51_CefotaximeAndBetaLactamaseInhibitor;

model CefotaximeAndBetaLactamaseInhibitor
  extends Pharmacolibrary.Drugs.ATC.J.J01DD51;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J01DD51</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Combination of cefotaxime, a third-generation cephalosporin antibiotic, with a beta-lactamase inhibitor used to treat a broad spectrum of bacterial infections, particularly those caused by beta-lactamase producing organisms. Cefotaxime is approved for clinical use, but this fixed ATC code refers to the combination with any beta-lactamase inhibitor, which may not be widely approved or formulated commercially.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated from published data about cefotaxime given intravenously in healthy adults, as no published PK data available for fixed combination with beta-lactamase inhibitor. Parameters are estimations extrapolated from cefotaxime studies only.</p><h4>References</h4><ol><li><p>Phillips, OA, et al., &amp; Maiti, SN (1997). SYN-1012: a new beta-lactamase inhibitor of penem skeleton. <i>The Journal of antibiotics</i> 50(4) 350–356. DOI:<a href=&quot;https://doi.org/10.7164/antibiotics.50.350&quot;>10.7164/antibiotics.50.350</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9186563/&quot;>https://pubmed.ncbi.nlm.nih.gov/9186563</a></p></li><li><p>Wildfeuer, A, et al., &amp; Pfaff, G (1989). Studies on the synergism of sulbactam and beta-lactam antibiotics under in vitro conditions and in healthy volunteers after intravenous administration. Antibacterial activity in vitro, compatibility and pharmacokinetics of the drugs in combination. <i>Arzneimittel-Forschung</i> 39(1) 94–100. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2785802/&quot;>https://pubmed.ncbi.nlm.nih.gov/2785802</a></p></li><li><p>Kokai-Kun, JF, et al., &amp; Sliman, J (2017). The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies. <i>Antimicrobial agents and chemotherapy</i> 61(3) –. DOI:<a href=&quot;https://doi.org/10.1128/AAC.02197-16&quot;>10.1128/AAC.02197-16</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28052855/&quot;>https://pubmed.ncbi.nlm.nih.gov/28052855</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end CefotaximeAndBetaLactamaseInhibitor;
